Cargando…

Time‐Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk

OBJECTIVE: It is unknown how the relationship between disease activity in rheumatoid arthritis (RA) and cardiovascular (CV) events may change over time. We examined the potentially time‐varying association of RA disease activity to CV events. METHODS: We used the CorEvitas prevalent RA registry. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Kazuki, Harrold, Leslie R., Middaugh, Nicole, Guan, Hongshu, Stryker, Scott, Karis, Elaine, Solomon, Daniel H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274374/ https://www.ncbi.nlm.nih.gov/pubmed/35403370 http://dx.doi.org/10.1002/acr2.11432

Ejemplares similares

Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Assessing clusters of comorbidities in rheumatoid arthritis: a machine learning approach
por: Solomon, Daniel H., et al.
Publicado: (2023)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis
por: Lin, Tzu‐Chieh, et al.
Publicado: (2017)

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
por: Lillegraven, Siri, et al.
Publicado: (2019)

Malignancy validation in a United States registry of rheumatoid arthritis patients
por: Fisher, Mark C, et al.
Publicado: (2012)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2015)

Granulosa cell tumor resection with subsequent onset of rheumatoid arthritis
por: Madill, Morgann, et al.
Publicado: (2020)

Towards the elucidation of the true impact of adipocytokines on cardiovascular risk in rheumatoid arthritis
por: Dessein, Patrick H, et al.
Publicado: (2013)

Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower(®) Registry
por: Nowell, W. Benjamin, et al.
Publicado: (2021)

Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
por: Harrold, Leslie R., et al.
Publicado: (2023)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
por: Harrold, Leslie R., et al.
Publicado: (2016)

Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial
por: Cohen, Stanley, et al.
Publicado: (2019)

Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout
por: Hansildaar, Romy, et al.
Publicado: (2021)

Cardiovascular risk score in Rheumatoid Arthritis
por: Wagan, Abrar Ahmed, et al.
Publicado: (2016)

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2017)

Rheumatoid Arthritis and Vascular Failure - Rheumatoid Arthritis Is a Risk Factor for Cardiovascular Disease-
por: Oyama, Jun-ichi, et al.
Publicado: (2019)

Time‐Varying Depressive Symptoms and Cardiovascular and All‐Cause Mortality: Does the Risk Vary by Age or Sex?
por: Bryant, Kelsey B., et al.
Publicado: (2020)

Diurnal patterns of sedentary time in rheumatoid arthritis: associations with cardiovascular disease risk
por: Fenton, Sally A M, et al.
Publicado: (2020)

Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2020)

Rheumatoid arthritis, as a clinical disease, but not rheumatoid arthritis-associated autoimmunity, is linked to cardiovascular events
por: Gouze, Hélène, et al.
Publicado: (2022)

Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis
por: Rodríguez-Rodríguez, Luis, et al.
Publicado: (2012)

Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis
por: Gualtierotti, Roberta, et al.
Publicado: (2017)

Modifiable cardiovascular risk factors in Rheumatoid Arthritis
por: Wagan, Abrar Ahmed, et al.
Publicado: (2017)

Misperception of the Cardiovascular Risk in Patients with Rheumatoid Arthritis
por: Alonso-Molero, Jéssica, et al.
Publicado: (2020)

Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis
por: Banerjee, Shubhasree, et al.
Publicado: (2020)

Cardiovascular Risk in Rheumatoid Arthritis: Literature Review
por: Hannawi, Suad MA, et al.
Publicado: (2021)

Frequency of Cardiovascular Manifestation in Patients With Rheumatoid Arthritis
por: Kumar, Pardeep, et al.
Publicado: (2021)

Management of Cardiovascular Disease Risk in Rheumatoid Arthritis
por: Dessein, Patrick H., et al.
Publicado: (2022)

Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis
por: Cordova Sanchez, Andres, et al.
Publicado: (2022)

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response
por: de Moel, Emma C., et al.
Publicado: (2019)

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d9ha6hlog879cbge7bndsgbgd2